Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.
Progentos Therapeutics has raised $65.0M in total funding. The most recent round was Series A. The last funding was announced in May 2024.
Progentos Therapeutics's investors include Longwood Fund, Mission BioCapital, Forbion Capital Partners, Alta Partners, Dolby Family Ventures.
Progentos Therapeutics is headquartered in Watertown, United States.
Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.
Progentos Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Progentos Therapeutics — Funding & Investors." VCBacked, May 14, 2024, https://www.vcbacked.co/company/progentos-therapeutics. Accessed September 15, 2026.
VCBacked. (2024). Progentos Therapeutics — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/progentos-therapeutics
{{cite web |title=Progentos Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/progentos-therapeutics |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated